#BEGIN_DRUGCARD DB00287

# AHFS_Codes:
52:92.00

# ATC_Codes:
S01EE04

# Absorption:
Systemically absorbed when administered to the eye.

# Biotransformation:
Travoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to its biologically active free acid. Systemically, travoprost free acid is metabolized to inactive metabolites via beta-oxidation of the &alpha;(carboxylic acid) chain to give the 1,2-dinor and 1,2,3,4-tetranor analogs, via oxidation of the 15-hydroxyl moiety, as well as via reduction of the 13,14 double bond.

# Brand_Mixtures:
Not Available

# Brand_Names:
Travatan
Travatan Z

# CAS_Registry_Number:
157283-68-6

# ChEBI_ID:
746859

# Chemical_Formula:
C26H35F3O6

# Chemical_IUPAC_Name:
propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl]cyclopentyl]hept-5-enoate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2244896

# Description:
Travoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a synthetic prostaglandin F2alpha analogue. [Wikipedia]

# Dosage_Forms:
Solution	Ophthalmic

# Drug_Category:
Antiglaucoma preparations and miotics
Antihypertensive Agents
Ophthalmologicals
Prostaglandin analogues

# Drug_Interactions:
Not Available

# Drug_Reference:
18452763	Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH: Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008 May;115(5):790-795.e4.
18983226	Arranz-Marquez E, Teus MA: Prostanoids for the management of glaucoma. Expert Opin Drug Saf. 2008 Nov;7(6):801-8.
19038618	Toris CB, Gabelt BT, Kaufman PL: Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008 Nov;53 Suppl1:S107-20.
19929706	Costagliola C, dell'Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F: Pharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother. 2009 Dec;10(17):2859-70.
9038626	Ferrari G, Scagliotti GV: Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients. Eur J Cancer. 1996 Dec;32A(13):2368-9.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
4.6

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
>16 mg/ml at 25.0Â°C

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Travoprost

# HET_ID:
Not Available

# Half_Life:
Terminal elimination half-life of travoprost free acid is 45 minutes.

# InChI_Identifier:
InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1

# InChI_Key:
InChIKey=MKPLKVHSHYCHOC-AHTXBMBWSA-N

# Indication:
Ophthalmic solution used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D01964

# LIMS_Drug_ID:
287

# Mechanism_Of_Action:
Travoprost free acid is a selective FP prostanoid receptor agonist and is believed to reduce intraocular pressure by increasing the drainage of aqueous humor, which is done primarily through increased uveoscleral outflow and to a lesser extent, trabecular outflow facility.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
500.5477

# Molecular_Weight_Mono:
500.238573467

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/tra1596.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA164781371

# Pharmacology:
Travoprost, an isopropyl ester prodrug, is a synthetic prostaglandin F2 alpha analogue that is rapidly hydrolyzed by esterases in the cornea to its biologically active free acid. The travoporst free acid is potent and highly selective for the FP prostanoid receptor.

# Predicted_LogP_Hydrophobicity:
4.02

# Predicted_LogS:
-4.8

# Predicted_Water_Solubility:
7.59e-03 g/l

# Primary_Accession_No:
DB00287

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
5282226

# PubChem_Substance_ID:
46507637

# RxList_Link:
http://www.rxlist.com/cgi/generic2/travoprost.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD01271

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F

# State:
liquid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Symptoms of overexposure include irritation to the skin, eyes, nose, throat, and respiratory tract.

# Update_Date:
2013-02-08 16:19:14 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Travoprost

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
16249494	Ota T, Aihara M, Narumiya S, Araie M: The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4159-63.
16505027	Thieme H, Schimmat C, Munzer G, Boxberger M, Fromm M, Pfeiffer N, Rosenthal R: Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility. Invest Ophthalmol Vis Sci. 2006 Mar;47(3):938-45.
18452763	Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH: Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008 May;115(5):790-795.e4.
18983226	Arranz-Marquez E, Teus MA: Prostanoids for the management of glaucoma. Expert Opin Drug Saf. 2008 Nov;7(6):801-8.
19038618	Toris CB, Gabelt BT, Kaufman PL: Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008 Nov;53 Suppl1:S107-20.
19697832	Neacsu AM: [Receptors involved in the mechanism of action of topical prostaglandines] Oftalmologia. 2009;53(2):3-7.
19929706	Costagliola C, dell'Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F: Pharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother. 2009 Dec;10(17):2859-70.
9038626	Ferrari G, Scagliotti GV: Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients. Eur J Cancer. 1996 Dec;32A(13):2368-9.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
PTGFR

# Drug_Target_1_GenBank_ID_Gene:
L24470

# Drug_Target_1_GenBank_ID_Protein:
456564

# Drug_Target_1_GeneCard_ID:
PTGFR

# Drug_Target_1_Gene_Name:
PTGFR

# Drug_Target_1_Gene_Sequence:
>1080 bp
ATGTCCATGAACAATTCCAAACAGCTAGTGTCTCCTGCAGCTGCGCTTCTTTCAAACACA
ACCTGCCAGACGGAAAACCGGCTTTCCGTATTTTTTTCAGTAATCTTCATGACAGTGGGA
ATCTTGTCAAACAGCCTTGCCATCGCCATTCTCATGAAGGCATATCAGAGATTTAGACAG
AAGTCCAAGGCATCGTTTCTGCTTTTGGCCAGCGGCCTGGTAATCACTGATTTCTTTGGC
CATCTCATCAATGGAGCCATAGCAGTATTTGTATATGCTTCTGATAAAGAATGGATCCGC
TTTGACCAATCAAATGTCCTTTGCAGTATTTTTGGTATCTGCATGGTGTTTTCTGGTCTG
TGCCCACTTCTTCTAGGCAGTGTGATGGCCATTGAGCGGTGTATTGGAGTCACAAAACCA
ATATTTCATTCTACGAAAATTACATCCAAACATGTGAAAATGATGTTAAGTGGTGTGTGC
TTGTTTGCTGTTTTCATAGCTTTGCTGCCCATCCTTGGACATCGAGACTATAAAATTCAG
GCGTCGAGGACCTGGTGTTTCTACAACACAGAAGACATCAAAGACTGGGAAGATAGATTT
TATCTTCTACTTTTTTCTTTTCTGGGGCTCTTAGCCCTTGGTGTTTCATTGTTGTGCAAT
GCAATCACAGGAATTACACTTTTAAGAGTTAAATTTAAAAGTCAGCAGCACAGACAAGGC
AGATCTCATCATTTGGAAATGGTAATCCAGCTCCTGGCGATAATGTGTGTCTCCTGTATT
TGTTGGAGCCCATTTCTGGTTACAATGGCCAACATTGGAATAAATGGAAATCATTCTCTG
GAAACCTGTGAAACAACACTTTTTGCTCTCCGAATGGCAACATGGAATCAAATCTTAGAT
CCTTGGGTATATATTCTTCTACGAAAGGCTGTCCTTAAGAATCTCTATAAGCTTGCCAGT
CAATGCTGTGGAGTGCATGTCATCAGCTTACATATTTGGGAGCTTAGTTCCATTAAAAAT
TCCTTAAAGGTTGCTGCTATTTCTGAGTCACCAGTTGCAGAGAAATCAGCAAGCACCTAG

# Drug_Target_1_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_1_General_References:
8300593	Abramovitz M, Boie Y, Nguyen T, Rushmore TH, Bayne MA, Metters KM, Slipetz DM, Grygorczyk R: Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem. 1994 Jan 28;269(4):2632-6.

# Drug_Target_1_HGNC_ID:
HGNC:9600

# Drug_Target_1_HPRD_ID:
08988

# Drug_Target_1_ID:
672

# Drug_Target_1_Locus:
1p31.1

# Drug_Target_1_Molecular_Weight:
40055

# Drug_Target_1_Name:
Prostaglandin F2-alpha receptor

# Drug_Target_1_Number_of_Residues:
359

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>Prostaglandin F2-alpha receptor
MSMNNSKQLVSPAAALLSNTTCQTENRLSVFFSVIFMTVGILSNSLAIAILMKAYQRFRQ
KSKASFLLLASGLVITDFFGHLINGAIAVFVYASDKEWIRFDQSNVLCSIFGICMVFSGL
CPLLLGSVMAIERCIGVTKPIFHSTKITSKHVKMMLSGVCLFAVFIALLPILGHRDYKIQ
ASRTWCFYNTEDIKDWEDRFYLLLFSFLGLLALGVSLLCNAITGITLLRVKFKSQQHRQG
RSHHLEMVIQLLAIMCVSCICWSPFLVTMANIGINGNHSLETCETTLFALRMATWNQILD
PWVYILLRKAVLKNLYKLASQCCGVHVISLHIWELSSIKNSLKVAAISESPVAEKSAST

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Receptor for prostaglandin F2-alpha (PGF2-alpha). The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Initiates luteolysis in the corpus luteum

# Drug_Target_1_SwissProt_ID:
P43088

# Drug_Target_1_SwissProt_Name:
PF2R_HUMAN

# Drug_Target_1_Synonyms:
PGF receptor
PGF2 alpha receptor
Prostanoid FP receptor

# Drug_Target_1_Theoretical_pI:
9.11

# Drug_Target_1_Transmembrane_Regions:
32-54
70-90
110-131
153-175
199-224
251-267
286-307

#END_DRUGCARD DB00287
